Xencor | XNCR - Себестоимость





Себестоимость Изменить Дата
AbbVie USD 4.22B 329M 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amgen USD 1.6B 187M 2026-03
AstraZeneca USD -204M 3.48B 2026-03
Biogen USD 797.5M 302M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Cytokinetics USD 160K 104.24M 2026-03
GlaxoSmithKline GBP 1.88B 736M 2026-03
J&J USD 8.07B 103M 2026-03
Karyopharm Therapeutics USD 1.48M 35.95M 2025-12
MacroGenics USD 10.12M 34.18M 2025-12
Merck USD 2.94B 380M 2026-03
Novartis USD 3.46B 83M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Xencor USD 61.66M 50.95M 2025-06